Verrica Pharmaceuticals opened higher at $3.94, compared with its previous close of $3.91. In the last trading session, the stock traded between $3.74 and $4.21. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Verrica Pharmaceuticals is now worth
$ 3.02
Resulting in a loss of
$ 96.98 (96.98%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
$-0.12 (-2.97%)
Day High
$4.21
Day Low
$3.74
Day Open
$3.94
Prev Close
$3.91
Volume
99,711
1W Return
9.34%
1M Return
-6.48%
3M Return
-29.41%
6M Return
-48.73%
1Y Return
3.66%
Fundamentals
Market Cap ($ Mn)
65
PE Ratio
-
PB Ratio
22.54
PEG Ratio
-
ROE
-
ROCE
-61.20%
EPS (TTM)
$-0.77
Investment Returns
1 Week
9.34%
1 Month
-6.48%
3 Months
-29.41%
6 Months
-48.73%
9 Months
-33.32%
Financials
Quarterly
All values in $ Mn
3.4
Mar 25
12.7
Jun 25
14.3
Sep 25
5.1
Dec 25
5.0
Mar 26
5.9
Jun 26
Updates
14Oct
Verrica Pharmaceuticals Q2FY26 Results: Revenue $5.9M, Net loss $13.2M
Total revenue was $5.9 million, down from $12.7 million in Q2FY25 due to the absence of a one-time $8.2 million milestone. U.S. YCANTH net product revenue grew 18.7% sequentially to $5.1 million, with dispensed units up 28%. GAAP net loss widened to $13.2 million as R&D expenses tripled to $6.0 million for the common warts program. Secured a non-dilutive financing facility of up to $27.5 million from Chairman Paul Manning to extend cash runway into 2028. Announced distribution partnership with Madomi Pharma for YCANTH in Israel, including up to $8.2 million in potential milestones.
29 days ago
21Jul
Verrica grants Medomie Pharma rights to YCANTH in Israel
Verrica Pharmaceuticals grants Medomie Pharma exclusive rights for YCANTH in Israel, receiving 60% of net sales and up to $8.2 million in milestones while manufacturing the product.
3mo ago
22Jun
Verrica doses first US patient in COVE-3 trial for YCANTH
Verrica Pharmaceuticals Inc. and its partner Torii Pharmaceutical have dosed the first patients in the U.S. and Japan for the COVE-3 trial, part of a global Phase 3 program for YCANTH (VP-102) targeting common warts. The program includes two pivotal studies, COVE-2 and COVE-3, with Torii funding 90% of the current trial budget. Verrica aims to secure the first FDA-approved therapy for common warts, a condition affecting 22 million people in the U.S.
